Deals

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties
Betta PharmaceuticalsGensciences

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties

Betta Pharmaceuticals Co., Ltd. (SHE: 300558) and Hangzhou Gensciences Biopharmaceuticals Co., Ltd. announced a collaboration under which Betta Pharmaceuticals has acquired the global exclusive rights to the ultra‑long‑acting monthly growth…

Astellas Inks Exclusive Option and License Deal for Audax's DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Astellas Inks Exclusive Option and License Deal for Audax’s DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Pfizer Launches Migraine Management Zone at China Pharmacy
NYSE: PFEOTC / retail

Pfizer Launches Migraine Management Zone at China Pharmacy

Cell-therapyNYSE: TAK

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

HKG: 2228HKG: 2629

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Lishan Biopharma Licenses Evogene’s LS-LBP-002 for Global Oncology Development
CancerEvogene

Lishan Biopharma Licenses Evogene’s LS-LBP-002 for Global Oncology Development

Show More